| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
125.61(B) |
| Last
Volume: |
944,433 |
Avg
Vol: |
1,608,675 |
| 52
Week Range: |
$332.58 - $485.53 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
40,257 |
161,595 |
276,622 |
637,091 |
| Total Sell Value |
$18,057,339 |
$68,277,055 |
$109,821,201 |
$217,614,554 |
| Total People Sold |
10 |
13 |
14 |
18 |
| Total Sell Transactions |
14 |
47 |
70 |
137 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2019-11-04 |
4 |
AS |
$199.77 |
$820,795 |
D/D |
(4,097) |
33,416 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2019-11-04 |
4 |
OE |
$86.52 |
$364,235 |
D/D |
4,097 |
37,513 |
|
- |
|
| Arbuckle Stuart A |
EVPChief Commercial Officer |
• – – |
2019-11-04 |
4 |
AS |
$201.62 |
$747,607 |
D/D |
(3,708) |
33,240 |
|
- |
|
| Arbuckle Stuart A |
EVPChief Commercial Officer |
• – – |
2019-11-04 |
4 |
OE |
$86.52 |
$330,578 |
D/D |
3,708 |
34,793 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2019-11-04 |
4 |
AS |
$200.20 |
$467,168 |
D/D |
(2,330) |
35,003 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2019-11-04 |
4 |
OE |
$86.52 |
$201,592 |
D/D |
2,330 |
37,333 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2019-11-01 |
4 |
AS |
$200.00 |
$19,365,992 |
D/D |
(96,822) |
106,287 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2019-11-01 |
4 |
OE |
$109.14 |
$11,170,756 |
D/D |
96,822 |
132,819 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2019-11-01 |
4 |
AS |
$200.00 |
$258,200 |
D/D |
(1,291) |
5,249 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2019-11-01 |
4 |
OE |
$152.74 |
$197,187 |
D/D |
1,291 |
6,540 |
|
- |
|
| Kearney Terrence C |
Director |
– • – |
2019-11-01 |
4 |
AS |
$200.00 |
$10,121,400 |
D/D |
(50,607) |
5,811 |
|
- |
|
| Kearney Terrence C |
Director |
– • – |
2019-11-01 |
4 |
OE |
$56.99 |
$3,756,367 |
D/D |
47,448 |
12,884 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2019-10-31 |
4 |
AS |
$200.00 |
$1,775,800 |
D/D |
(8,879) |
106,287 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2019-10-31 |
4 |
OE |
$131.89 |
$1,171,051 |
D/D |
8,879 |
115,166 |
|
- |
|
| Kearney Terrence C |
Director |
– • – |
2019-10-31 |
4 |
AS |
$200.00 |
$368,200 |
D/D |
(1,841) |
8,970 |
|
- |
|
| Kewalramani Reshma |
EVP and CMO |
• – – |
2019-10-30 |
4 |
AS |
$199.00 |
$608,343 |
D/D |
(3,057) |
13,098 |
|
- |
|
| Kewalramani Reshma |
EVP and CMO |
• – – |
2019-10-30 |
4 |
OE |
$155.57 |
$475,577 |
D/D |
3,057 |
16,155 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2019-10-25 |
4 |
AS |
$195.01 |
$840,688 |
D/D |
(4,311) |
33,416 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2019-10-25 |
4 |
OE |
$91.05 |
$392,517 |
D/D |
4,311 |
37,727 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2019-10-22 |
4 |
AS |
$194.37 |
$713,144 |
D/D |
(3,669) |
31,553 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2019-10-22 |
4 |
OE |
$155.57 |
$570,786 |
D/D |
3,669 |
35,222 |
|
- |
|
| Kewalramani Reshma |
EVP and CMO |
• – – |
2019-10-22 |
4 |
AS |
$189.00 |
$120,582 |
D/D |
(638) |
13,098 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2019-10-22 |
4 |
AS |
$190.00 |
$20,487,890 |
D/D |
(107,831) |
106,287 |
|
- |
|
| Leiden Jeffrey M |
CEO & President |
• • – |
2019-10-22 |
4 |
OE |
$109.14 |
$12,574,276 |
D/D |
107,831 |
141,698 |
|
- |
|
| Mcglynn Margaret G |
Director |
– • – |
2019-10-22 |
4 |
AS |
$190.00 |
$3,800,000 |
D/D |
(20,000) |
4,124 |
|
- |
|
1777 Records found
|
|
Page 30 of 72 |
|
|
2.49 (0.51%) 
